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Monoclonal antibodies (mAb) have emerged as a promising 
approach to treating a range of tumor types. In contrast to con-
ventional chemotherapy, which affects all rapidly dividing 
cells, mAb aim to inhibit specific molecular pathways that are 
necessary for tumor growth and maintenance.1 Among the 
most encouraging mAb is trastuzumab, which targets the 
human epidermal growth factor receptor 2 and is indicated in 
the treatment of breast cancer2; bevacizumab, which inhibits 
vascular endothelial growth factor and is indicated in the treat-
ment of a range of diseases, including colorectal, lung, and 
ovarian cancer3; and cetuximab, which blocks the epidermal 
growth factor receptor and is indicated in the treatment of 
colorectal and lung cancer.4 Despite initial excitement over 
dramatic tumor regressions, however, mAb in general have 
achieved only limited improvements in overall survival 
because of primary resistance in some patients and the often 
rapid occurrence of secondary resistance in many responders.5 
Combination strategies involving multiple mAb and 
chemotherapies have been increasingly used in an attempt to 
prevent or combat the emergence of secondary resistance. A 
number of recent studies have shown that combining 2 mAb 
may lead to an increase in median progression-free survival 
compared with monotherapy.6,7 There is also growing interest 
in whether immunotherapies that can harness endogenous 
anti-tumor immunity by modifying immune regulatory mech-
anisms can help consolidate impressive clinical responses 
from mAb into long-lasting clinical remissions.1,8,9 Although 
combination strategies seem to be delivering improved clini-
cal outcomes, an important consideration when combining 
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Abstract
Combination strategies involving chemotherapy and monoclonal antibodies (mAb) are commonly used in attempts to 
produce better clinical outcomes. This practice has led to new and ongoing toxicities that may lead to reductions in dose 
or noncompliance, limiting the effectiveness of treatment. Viscum album L (VA) preparations are widely used in Europe as 
additive therapy and have been associated with reduced chemotherapy-related adverse reactions and increased health-
related quality of life. Concomitant VA therapy might also reduce toxicity related to mAb. This retrospective study 
investigated the safety of combined treatment with VA and mAb in cancer patients. A total of 43 patients had combined 
therapy (474 exposures); 12 had VA without mAb (129 exposures), and 8 had mAb without VA (68 exposures). Most 
patients (89.3%) received concomitant chemotherapy or supportive therapies. A total of 34 patients (60.7%) experienced 
142 adverse events (AEs). Leucopenia (14.1% of all events), acneiform rash (8.5%), and stomatitis (6.3%) occurred 
most frequently. Longitudinal logistic regression analysis suggested a nearly 5 times higher odds of experiencing an AE 
following treatment with mAb compared with mAb plus VA (95% CI = 1.53-16.14). Our results, together with theoretical 
consideration of potential botanical-drug interactions, suggest that combined treatment with VA and mAb is safe.
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multiple therapies, especially cytotoxic drugs with narrow-
therapeutic indexes, is the elevated risk of adverse drug-drug 
interactions.10 Despite being “targeted” therapies, these drugs 
affect multiple organ systems, and their chronic and combined 
use has led to the identification of new toxicities that can 
impair health-related quality of life (HRQL) and require long-
term management.11 Importantly, ongoing toxicity caused by 
mAb can lead to reductions in dose or noncompliance, 
thereby, limiting the effectiveness of treatment. Supportive 
therapies that can relieve toxicity associated with mAb and 
chemotherapy or improve HRQL are, therefore, of significant 
interest.
Viscum album L (VA or European mistletoe) prepara-
tions are widely used as additive cancer therapy in Europe, 
especially in German-speaking countries, and have been 
associated with a reduction in chemotherapy-related adverse 
drug reactions and increased HRQL.12,13 Furthermore, it has 
been suggested that VA preparations can induce clinically 
beneficial immunomodulation through lectin-carbohydrate 
interactions, leading to enhancement of interleukin-12 
secretion and natural killer cell function.14,15 Therefore, use 
of VA therapy preparations alongside mAb might help 
improve the balance of the innate immune system, thereby 
decreasing treatment-related toxicities and possibly even 
helping in overcoming tumor-induced immunosuppression 
and treatment resistance. Whereas at least 1 group has thor-
oughly investigated the safety of combined use of VA prep-
arations and the chemotherapeutic agent, gemcitabine,16 we 
were unable to find information regarding the safety of 
combined use of VA preparations and mAb. The present 
study describes the combined use of intravenously adminis-
tered Helixor VA preparations and a variety of mAb in can-
cer patients of the Havelhoehe Hospital in Berlin and 
investigates the safety of this combinatorial approach. 
Theoretical considerations regarding the potential for nega-
tive botanical-drug interactions between VA preparations 
and mAb are also discussed.
Methods
Study Design and Setting
A retrospective cohort study was conducted to assess the 
safety of combined (same-day) intravenous infusions of 
mAb and VA preparations manufactured by Helixor 
Heilmittel GmbH (Rosenfeld, Germany). The Network 
Oncology (NO), a joint clinical registry of German hospi-
tals and outpatient practitioners specialized in integrative 
medicine, was used during this study.17 The NO database 
contains patient information and data on cancer diagnoses, 
therapies, adverse events (AEs), and disease progress 
extracted from patient files and recorded using the 
QuaDoSta (Quality management, Documentation, and 
Statistics) software that was developed at Havelhoehe 
Research Institute. Ethical approval for the NO project was 
obtained from the Medical Association Berlin.
Study Participants
Data of consenting cancer patients treated between August 
2005 and November 2014 were assessed between July 2014 
and July 2015. We found 95 patients who had received both 
Helixor VA preparations and mAb at any time during their 
treatment. All patients had an ECOG performance status of 
0 to 2, and no patient was ineligible based on comorbidities 
(ie, no evidence of refractory hypertension, internal bleed-
ing, danger of perforation, or treatment with mAb within 4 
weeks of surgery). Details of treatment with mAb or VA 
preparations, including dates, doses, routes of administra-
tion, concomitant medications, and associated AEs, along 
with demographic, diagnosis, and disease progression data 
were extracted. Patients were assigned to 1 or more of 3 
treatment groups based on documented timing of treatment 
with mAb and VA preparations (Figure 1). Note that it was 
possible for patients to be assigned to different treatment 
groups at different times throughout their treatment. If a VA 
preparation and mAb therapy were received by a patient on 
the same day, the patient was described as receiving com-
bined therapy. A patient was described as receiving VA 
therapy if they received one or more VA infusions, where 
they did not receive mAb for at least 1 month either side of 
the VA application. Likewise, mAb therapy refers to a 
patient not receiving a VA infusion for at least 1 month 
either side of treatment with mAb. A 1-month washout 
period was specified to eliminate any carryover effects and 
to avoid confusion over the causality of delayed or enduring 
AEs. Because of the complex nature of cancer treatment, 
some patients in all 3 groups received concomitant chemo-
therapy or supportive therapies (eg, antiemetic or pain med-
ication). Patients were excluded from the study if they did 
not meet the criteria for at least 1 of the 3 treatment groups 
or if they had missing or invalid information regarding 
dates of treatment with mAb and VA preparations, specific 
drug names, concomitant medications, database identifica-
tion number, date of birth, gender, date of diagnosis, or 
ICD-10 code. Although data for all routes of administration 
and types of VA preparations and targeted therapies were 
collected, our analysis was limited to intravenously admin-
istered Helixor VA preparations and intravenously adminis-
tered mAb.
Outcomes
The primary outcome was occurrence of an AE during or 
shortly after combined therapy, VA therapy, or mAb ther-
apy. An AE was defined as “any untoward medical occur-
rence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not 
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necessarily have to have a causal relationship with this 
treatment”18(p 2). AEs were chosen as the primary outcome 
rather than adverse drug reactions (which are drug specific) 
because in situations where multiple medications are 
administered concomitantly (eg, a VA preparation, anti-
emetic medication, a mAb, and a chemotherapeutic agent), 
attributing causality of an AE to a single medication can be 
difficult. AEs that were clearly disease related or could be 
definitely attributed to a previous therapy were excluded. 
All other AEs (eg, could be related to mAb, VA, chemo-
therapy, or supportive therapies) were classified as Medical 
Dictionary for Regulatory Activities (MedDRA) 15.0 pre-
ferred terms and grouped by System Organ Class. Secondary 
outcomes were the type and frequency of specific AEs and 
the number of serious AEs.
Statistical Analysis
Patient characteristics and exposure to mAb, Helixor VA 
preparations, chemotherapy, and supportive therapies were 
compared between treatment groups. The relative frequency 
of patients experiencing 1 or more AEs, the number of 
exposures to which AEs occurred, the total number and 
types of AEs, the number of AEs per 100 exposures (crude 
incidence rates), and the number of AEs classified as seri-
ous were described for each treatment group. To assess 
which demographic and treatment factors were associated 
with AEs, a longitudinal logistic regression model was fit 
using the generalized estimating equations (GEE) method 
to account for the multiple observations per person. An 
exchangeable covariance structure was used to model the 
correlation of the repeated measurements over time. In the 
adjusted model, age at treatment, concomitant chemother-
apy (no, yes), and concomitant supportive therapies (no, 
yes) were included as time-varying covariates. Use of 
time-varying covariates means that confounders can change 
over time. For example, a patient could be classified as hav-
ing combined therapy on one occasion followed by mAb 
therapy on another occasion (as long as the washout period 
was satisfied by there being at least 1 month between differ-
ent types of therapies). Baseline covariates included were 
gender (male, female) and Union for International Cancer 
Control stage at first treatment (UICC I-II, UICC III-IV, not 
applicable or unknown). Odds ratios (ORs), 95% CIs, and P 
values were calculated, and the level of significance (α) was 
set at .05. All analyses were conducted using R version 
3.1.2.19 GEE models used the geepack package.20
Results
Out of 95 patients treated with Helixor VA preparations and 
mAb, 56 were selected for inclusion in this study (Figure 1). 
A total of 36 patients were excluded because they were only 
treated with VA and mAb on separate days but within 1 
month of each other. One patient was excluded for not hav-
ing a database identification number, which was necessary 
for acquiring basic patient information; 1 patient was 
excluded for not having a date of treatment; and another 
patient was excluded for only receiving subcutaneous VA 
despite intravenous VA being prescribed. Among the 
remaining 56 patients representing 671 exposures, 43 
patients had 474 exposures to combined therapy, 12 patients 
had 129 exposures to VA therapy, and 8 patients had 68 
exposures to mAb therapy. Seven patients were included in 
more than 1 treatment group: 2 patients had combined ther-
apy and VA therapy at different times, whereas 5 patients 
had VA therapy and mAb therapy. The number of exposures 
per patient ranged from 1 to 44, with a median of 6 and 
interquartile range (IQR) of 3 to 18 for combined therapy, 
from 1 to 33 with a median of 8 (IQR = 2-17) for VA 
95 patients received Viscum album L. (Helixor) preparations and monoclonal antibodies
56 patients included in study
(671 exposures)





43 patients received combined 
therapy
(474 exposures)
39 patients excluded from study
- 36 not classified as combined, VA or mAb therapy
- 1 with missing identification number
- 1 with missing dates of exposure
- 1 with subcutaneous VA only (no intravenous)
Figure 1. Flowchart of participant selection from 95 patients whose medical records were reviewed.
Abbreviations: VA, Viscum album L; mAb, monoclonal antibodies.
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Table 2. Patient Exposure to Combinations of VA Preparations and mAb.a
Number of Patients 
Exposed (Total Exposures) Helixor A Helixor M Helixor P
mAb Therapy 
(No VA) Total
Ado-trastuzumab emtansine 2 (17) — — — 2 (17)
Bevacizumab 19 (87) 10 (94) 2 (7) 3 (18) 32 (206)
Cetuximab 8 (104) 5 (31) 1 (11) 1 (4) 13 (150)
Ofatumumab — — — 1 (3) 1 (3)
Panitumumab 1 (3) 1 (9) — 1 (1) 3 (13)
Rituximab — 1 (1) 1 (3) 1 (6) 3 (10)
Trastuzumab 8 (94) 1 (13) — 3 (36) 11 (143)
VA therapy (no mAb) 6 (32) 6 (55) 3 (42) — 12 (129)
Total 38 (337) 20 (203) 6 (63) 8 (68) 56 (671)
Abbreviations: VA, Viscum album L; mAb, monoclonal antibodies.
aValues represent the number of patients exposed, with the total number of exposures in parentheses.
therapy, and from 1 to 25 with a median of 8 (IQR = 5-9) for 
mAb therapy. The total period of time during which patients 
received therapies ranged from 1 day to 2.4 years, with a 
median of 3.5 months (IQR = 0.8-10.8 months), for com-
bined therapy; 1 day to 6.1 years, with a median of 7.9 
months (IQR = 1.6-13.8 months), for VA therapy; and 1 day 
to 3.3 years, with a median of 4.9 months (IQR = 1.3-13.3 
months), for mAb therapy.
Demographic and diagnosis information for all included 
patients are summarized in Table 1. Patients in the mAb 
therapy group were generally younger at the age of first 
treatment and more likely to be female and suffering from 
breast cancer; treatment more frequently began at an early 
UICC stage. Data for the time-varying factor—age at treat-
ment—were skewed in both the individual therapy groups.
The total number of exposures to different combinations 
of mAb and VA are presented in Table 2. Consecutive infu-
sion of Helixor Abietis and cetuximab (8 patients, 104 
exposures) was the most frequent combination, followed by 
Helixor Mali and bevacizumab (10 patients, 94 exposures) 
and Helixor Abietis and trastuzumab (8 patients, 94 expo-
sures). Although 7 mAb were documented, 92% of all expo-
sures to mAb were to bevacizumab, trastuzumab, or 
cetuximab.
Concomitant use of chemotherapeutic agents and sup-
portive medications, such as antiemetic drugs, in addition to 
VA or mAb was reported at least once in 50 (89%) patients. 
Table 3 shows the number of exposures that involved con-
comitant chemotherapy only (11%, 4%, and 10%), support-
ive therapy only (16%, 2%, and 9%), chemotherapy and 










Age at first exposure, median (IQR) 59 (50-69) 59 (50-70) 58 (46-66) 49 (48-63)
Age at exposure,a median (IQR) 65 (51-72) 69 (55-72) 46 (45-74) 51 (49-63)
Gender, n (%)
 Male 22 (39.3) 18 (41.9) 6 (50.0) 2 (25.0)
 Female 34 (60.7) 25 (58.1) 6 (50.0) 6 (75.0)
Location of tumor, n (%)
 Breast 15 (26.8) 10 (23.2) 2 (16.7) 4 (50.0)
 Digestive system 32 (57.1) 27 (62.8) 6 (50.0) 3 (37.5)
 Hematological system 3 (5.4) 2 (4.7) 2 (16.7) 1 (12.5)
 Respiratory system 2 (3.6) 1 (2.3) 1 (8.3) —
 Urogenital system 4 (7.1) 3 (7.0) 1 (8.3) —
UICC stage at first treatment, n (%)
 I-II 8 (14.3) 5 (11.6) 2 (16.7) 3 (37.5)
 III-IV 38 (67.9) 30 (69.8) 7 (58.3) 4 (50.0)
 Not applicable or unknown 10 (17.9) 8 (18.6) 3 (25.0) 1 (12.5)
Abbreviations: VA, Viscum album L; mAb, monoclonal antibodies; IQR, interquartile range; UICC, Union for International Cancer Control.
aMedian age calculated from all exposures allowing age of patients to increase over time.
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supportive therapy (50%, 16%, and 19%), or no concomi-
tant therapy (23%, 78%, and 62%) for combined, VA, and 
mAb therapies, respectively. Dexamethasone, a corticoste-
roid used to counteract adverse reactions to chemotherapy 
agents, was the most frequently used concomitant therapy 
(20 patients, 139 exposures). The second and third most fre-
quent premedication regimens consisted of dexamethasone 
together with dimethindene maleate (Fenistil), an antihista-
mine used to prevent hypersensitivity reactions (16 patients, 
94 exposures) and dimethindene maleate alone (5 patients, 
34 exposures). Of the total exposures to combined therapy, 
VA therapy, and mAb therapy, 61%, 20%, and 29% of expo-
sures involved same-day chemotherapy (with or without 
supportive therapy), respectively. The most frequent che-
motherapy regimen involved injections of folinic acid and 
fluorouracil, followed by slow infusion of fluorouracil 
through a Baxter pump (10 patients, 59 exposures). Other 
frequent chemotherapy regimens were as stated above but 
with the addition of oxaliplatin (FOLFOX: 12 patients, 52 
exposures) or irinotecan (FOLFIRI: 5 patients, 48 
exposures).
Out of 56 patients included in the study, 34 (61%) expe-
rienced a total of 142 AEs on 85 exposures (Table 4). 
Among patients who experienced an AE, the median num-
ber of events per exposure was 1 (IQR = 1-2; range = 1-9) 
and the median number of events per patient overall was 3 
(IQR = 1-6; range = 1-25). The highest incidence of AEs 
was in the mAb therapy group, with 5 out of 8 patients 
(63% of patients) experiencing a total of 22 events on 18 
exposures (27% of exposures). This was followed by the 
combined therapy group, with 24 out of 43 patients (56%) 
experiencing 112 events on 61 exposures (13%), and the VA 
therapy group, with 5 out of 12 patients (42%) experiencing 
8 events on 6 exposures (5%). Crude rates of AEs were cal-
culated as 32 events occurring per 100 exposures to mAb 
therapy, 21 events per 100 exposures to combined therapy, 
and 6 events per 100 exposures to VA therapy. Apart from 
designation of AEs to 1 of the 3 therapy types based on tim-
ing of the event, specific causality was not attributed 
because many of the events could have been reactions to 
concomitantly applied mAb, VA, chemotherapeutic agents, 
and/or supportive therapies (Table 4). The most common 
events following exposure to combined therapy were leuco-
penia (16% of patients), stomatitis (14%), diarrhea and mal-
aise (each 9%), skin reactions, rash, acne, nausea, chills, 
and palmar-plantar erythrodysesthesia (each 7%). For mAb 
therapy, common reactions were leucopenia and malaise 
(each 25%), neutropenia, weakness, acneiform rash, and 
anemia (each 14%), and for VA therapy, they were skin 
reaction or rash (25%), pruritus (17%), and urticaria (8%).
Of the total 142 AEs to 85 exposures, 26 events (18%) to 
13 exposures (15%) were classified as serious because they 
required hospitalization, prolongation of existing hospital-
ization, or resulted in persistent or significant incapacity 
(Table 4). One patient (8%) in the VA therapy group experi-
enced a serious AE (unspecified hospitalization), which 
was attributed to concomitant chemotherapy. One patient 
(13%) in the mAb group was hospitalized on 2 occasions: 
once following exposure to rituximab with concomitant 
paracetamol and dimethindene maleate (malaise) and once 
following exposure to ofatumumab with concomitant 
paracetamol and dimethindene maleate (unspecified hospi-
talization). Seven patients (16%) experienced 23 serious 
AEs to 10 exposures of combined therapy. Of these 10 
exposures, 6 involved concomitant chemotherapies, and 9 
involved concomitant supportive therapies, making attribu-
tion of causality difficult.
AE rates (ie, total exposures with ≥1 AE/total patient 
days of exposure) and results of the longitudinal analysis of 
AEs are shown in Table 5. Univariable analyses did not 
reveal any significant associations between demographic or 
treatment factors and AEs. A multivariable GEE model 
adjusted for treatment exposure, age at treatment, gender, 
UICC stage, concomitant chemotherapy, and concomitant 
supportive therapy indicated increased odds of experiencing 
an AE following mAb therapy compared with combined 
therapy (OR = 4.97; 95% CI = 1.53-16.14; P = .008). AE 
rates and the directions of ORs suggest that VA therapy and 
female gender were negatively associated with AEs, and 
stage III to IV cancer, concomitant chemotherapy, and 
Table 3. Patient Exposure to Concomitant Chemotherapy or Supportive Therapies.a
Number of Patients 
Exposed (Total Exposures)
No Concomitant 
Therapies Chemotherapyb Supportive Therapiesc
Chemotherapy and 
Supportive Therapies
Combined therapy 23 (108) 12 (55) 11 (75) 33 (236)
VA therapy 11 (101) 2 (5) 1 (3) 5 (20)
mAb therapy 5 (42) 3 (7) 2 (6) 3 (13)
All patients 35 (251) 17 (67) 14 (84) 40 (269)
Abbreviations: VA, Viscum album L; mAb, monoclonal antibodies.
aValues represent the number of patients exposed, with the total number of exposures in parentheses.
bChemotherapy agents included fluorouracil, bendamustine, capecitabine, carboplatin, cisplatin, cyclophosphamide, docetaxel, fludarabine, folinic acid, 
gemcitabine, irinotecan, oxaliplatin, paclitaxel, pemetrexed, and vinorelbine.
cSupportive therapies included atropine, clemastine, dexamethasone, dimethindene maleate, paracetamol, and prednisolone.
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Table 4. Frequency of Nonserious and Serious Adverse Events Classified as MedDRA-Preferred Terms and Grouped by System 
Organ Class.a
System Organ Class Preferred Term
All Patients,  
n = 56 (671)
Combined Therapy, 
n = 43 (474)
VA Therapy, 
n = 12 (129)
mAb Therapy, 
n = 8 (68)
Blood and lymphatic system Anemia (m, c) 1 — — 1
Granulocytopenia (m, c) 1 1 — —
Leucopenia (m, c) 20 9 — 11
Neutropenia (m, c) 2 1 — 1
Thrombocytopenia (m, c) 2 2 — —
Gastrointestinal Colitis (m, c) 1 1 — —
Diarrhea (m, c, v) 6 6 — —
Nausea/Vomiting (m, c, v) 7 (5) 7 (5) — —
Stomatitis/Mucositis (m, c) 9 9 — —
General disorders and administration site Asthenia (m, c) 2 (1) 1 (1) — 1
Chills (m, v, c) 4 4 — —
Decreased appetite (m, c) 1 1 — —
Fatigue (m, v, c) 2 2 — —
Hyperhidrosis (m, c) 1 1 — —
Malaise (m, v, c) 6 (3) 4 (2) — 2 (1)
Pain (m, v, c) 1 1 — —
Pyrexia (m, v, c) 2 2 — —
Swelling (m, v, c) 1 1 — —
Unspecified hospitalization (m, v, c) 2 (2) — 1 (1) 1 (1)
Immune system Hypersensitivity (m, v, c) 2 2 — —
Infections and infestations Abscess (c) 2 (1) 2 (1) — —
Eye infection (m, c) 2 2 — —
Fungal infection (m, c) 1 — — 1
Gingivitis (m, c) 1 1 — —
Oral herpes 1 1 — —
Pyelonephritis (m, c) 1 (1) 1 (1) — —
Septic encephalopathy 1 (1) 1 (1) — —
Skin infection (m, c) 1 1 — —
Stoma site infection (m, c) 1 — — 1
Urinary tract infection (m, c) 3 3 — —
Urosepsis (c) 1 (1) 1 (1) — —
Musculoskeletal and connective tissue Back pain (m, c) 1 1 — —
Nervous system Cognitive disorder (c) 2 (2) 2 (2) — —
Dizziness (m, c) 3 (3) 3 (3) — —
Polyneuropathy (c) 5 (1) 4 (1) — 1
Somnolence (m, c) 2 (2) 2 (2) — —
Renal and urinary Bladder disorder (m, c) 1 1 — —
 Enuresis 2 (2) 2 (2) — —
Respiratory, thoracic, and mediastinal Dyspnea (m, c) 1 1 — —
Rhinorrhea (m, v, c) 1 1 — —
Skin and subcutaneous Acneiform rash (m) 12 10 — 2
Dry skin (m, c) 3 3 — —
Eczema (m, c) 1 1 — —
Generalized erythema (m, v, c) 2 2 — —
Palmar-plantar erythrodysesthesia 
(m, c)
3 3 — —
Pruritus (m, v, c) 5 2 3 —
Rosacea 1 1 — —
Skin reaction/Rash (unspecified) 
(m, v, c)
7 4 3 —
Urticaria (m, v, c) 1 — — —
Vascular disorders Hemorrhage (m, c) 1 (1) 1 (1) — —
Total 142 (26 SAE) 112 (23 SAE) 8 (1 SAE) 22 (2 SAE)
Abbreviations: MeDRA, Medical Dictionary for Regulatory Activities; VA, Viscum album L; mAb, monoclonal antibodies; n, number of patients with the number of treatment 
exposures in parentheses; SAE, serious adverse events.
aValues represent the total number of documented adverse events, with the number of events classified as serious shown in parentheses. Causality was not attributed to 
adverse events because many of the events could have been reactions to concomitantly applied mAb (m), chemotherapeutic agents (c), VA (v), and/or supportive therapies 
(not indicated).
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supportive therapies were positively associated with AEs; how-
ever, none of these associations was statistically significant.
Rates for serious AEs were similar for combined ther-
apy (2%) and mAb therapy (3%) and were lower for VA 
therapy (0.8%). Significance tests were not performed 
for serious AEs because of the low number of events. 
The incidence rates of AEs according to mAb exposure 
are shown in Table 6. The highest incidence in the com-
bined therapy group was for bevacizumab. Bevacizumab 
had an even higher incidence in the mAb group; how-
ever, the small sample size of the mAb group prevents 
an accurate assessment of incidence according to spe-
cific therapies.
Discussion
In this retrospective cohort study investigating the safety of 
combined therapy with Helixor VA preparations and mAb, 
the highest incidence of AEs occurred after exposure to 
mAb therapy. A multivariable GEE model indicated that the 
odds for patients experiencing an AE following mAb ther-
apy were nearly 5 times higher compared with that for mAb 
plus VA. Whereas AE rates suggested that concomitant che-
motherapy was positively associated with AEs (16% of all 
exposures with chemotherapy vs 10% without chemother-
apy), this association was not statistically significant. This 
is most likely a result of sample size limitations. Furthermore, 








Combined therapy 61/474 (12.9) 1.00 1.00  
VA therapy 6/129 (4.7) 0.65 (0.21-2.01) .457 0.77 (0.21-2.76) .686
mAb Therapy 18/68 (26.5) 2.80 (0.85-9.22) .090 4.97 (1.53-16.14) .008
Age (mean ± SD) 62.9 ± 10.0 1.01 (0.98-1.03) .501 1.00 (0.97-1.03) .903
Male 36/316 (11.4) 1.00 1.00  
Female 49/355 (13.8) 1.15 (0.52-2.55) .731 0.89 (0.43-1.88) .768
UICC I-II 7/111 (6.3) 1.00  
UICC III-IV 70/457 (15.3) 2.25 (0.74-6.82) .151 3.42 (0.90-12.93) .070
NA/Unknown 8/103 (7.8)  
Breast 20/191 (10.5) 1.00  
Digestive 58/407 (14.3) 1.30 (0.39-4.30) .668  
Hematological 3/15 (20.0) 1.25 (0.22-7.23) .800  
Respiratory 1/19 (5.3) 0.29 (0.06-1.30) .107  
Urogenital 3/39 (7.7) 1.36 (0.18-10.07) .767  
Chemotherapy = no 32/335 (9.6) 1.00 1.00  
Chemotherapy = yes 53/336 (15.8) 1.18 (0.71-1.98) .522 1.09 (0.61-1.93) .770
Supportive therapy = no 33/318 (10.4) 1.00 1.00  
Supportive therapy = yes 52/353 (14.7) 1.18 (0.73-1.91) .505 1.23 (0.69-2.20) .474
Abbreviations: AE, adverse event; OR, odds ratio; VA, Viscum album L; mAb, monoclonal antibodies; UICC, Union for International Cancer Control.
aAE rates are shown as the number of exposures with ≥1 adverse event over the total number of exposures (%).
Table 6. Incidence of AEs According to Monoclonal Antibody Exposure.
Monoclonal Antibodies
Combined Therapy mAb Therapy
Exposures Exposures With ≥1 AE (%) Exposures Exposures With ≥1 AE (%)
Ado-trastuzumab emtansine 17 1 (5.8) — —
Bevacizumab 188 32 (17.0) 18 9 (50.0)
Cetuximab 146 20 (13.7) 4 2 (50.0)
Ofatumumab — — 3 2 (66.7)
Panitumumab 12 1 (8.3) 1 1 (100.0)
Rituximab 4 0 6 1 (16.7)
Trastuzumab 107 7 (6.5) 36 3 (8.3)
Abbreviations: AE, adverse event; mAb, monoclonal antibodies.
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chemotherapy AEs might be underreported compared with 
AEs related to mAb or VA because of the well-known and 
expected toxicity profiles of chemotherapeutic agents. The 
rate of serious AEs did not appear to differ between com-
bined and mAb therapies and was lower for VA therapy.
The most frequent AEs related to combined therapy were 
development of an acneiform rash, leucopenia, and stomati-
tis/mucositis, none of which were serious. Serious AEs 
related to combined therapy were mostly nervous system 
related, such as dizziness, nausea and vomiting, infections, 
or malaise. The toxicity profile of the combined therapy 
group was similar to that of the targeted therapy group, for 
which leucopenia, acneiform rash, and malaise were the 
most frequent events. Apart from an unspecified hospital-
ization attributed to chemotherapy, all AEs in the VA ther-
apy group were skin-related reactions.
It is important to acknowledge a number of limitations of 
our study. First, of the 95 medical records initially reviewed, 
36 patients were excluded for not satisfying the 1-month 
washout period. Specification of a washout period was 
important for this study because many of the observed AEs 
can have a delayed onset or be long-lasting (eg, leucopenia, 
acneiform rash). However, this resulted in small sample 
sizes for both the individual therapy groups and a conse-
quent decrease in statistical power. Because of the retro-
spective and nonrandomized nature of this study, patient 
characteristics and diagnoses were not balanced across 
treatment groups. Factors considered as potential confound-
ers (ie, age, gender, UICC stage, concomitant chemother-
apy, and supportive therapies) were included in multivariable 
analysis; however, it is likely that unmeasured confounders, 
such as previous surgery or unmeasured comorbidity, exist. 
Furthermore, although mechanistically it would make sense 
to assess different mAb separately and to also consider the 
role of therapy dose, small sample sizes and heterogeneity 
prevented us from doing this. Another limitation related to 
the use of retrospective data is that AE descriptions were 
often not detailed enough to enable grading in terms of 
severity. Some descriptions were vague, such as “unspeci-
fied hospitalization” or “skin reaction,” and some mild, 
expected AEs such as fatigue or headaches were probably 
underreported. Importantly, however, we were able to iden-
tify all serious AEs based on hospitalization and AE man-
agement data.
Overall, although our results must be interpreted with 
care, they provide a first picture of the current application 
and toxicity profile of a combination strategy involving VA 
and mAb. Furthermore, to our knowledge, this is the first 
attempt to investigate the safety of such a strategy. The 
types and frequencies of AEs and serious AEs observed in 
the combined and mAb groups in our study are consistent 
with adverse drug reactions to mAb and chemotherapeutic 
agents described in the literature.21-27 In a phase II trial 
treating metastatic colorectal cancer patients with FOLFOX 
and cetuximab, 76% of patients had an AE (grades 3-4).28 
The most frequent events were neutropenia (30%), skin 
reactions (18%), rash (11%), and diarrhea (8%). In another 
study, a phase III trial comparing FOLFIRI plus cetuximab 
with FOLFIRI plus bevacizumab in colorectal cancer, 71% 
of patients in the cetuximab group and 64% of patients in 
the bevacizumab group had AEs (grades 3-4), with the most 
frequent events being hematotoxicity (cetuximab, 25%; 
bevacizumab, 21%), skin reactions (26% and 2%), and diar-
rhea (11% and 14%).29 Additionally, common grade 1 to 2 
events included acneiform rash (61%), nausea (45%), and 
stomatitis (38%). In our study, 55.8% of patients exposed to 
combined therapy (VA plus mAb with or without chemo-
therapy) reported AEs. This incidence is for events of any 
grade; however, low-grade events were most likely under-
reported. The most frequent events for combined therapy 
were leucopenia (16% of patients); stomatitis (14%); skin 
reactions, including rash and dry skin (12%); diarrhea; and 
malaise (each 9%). The rates of AEs observed in our study 
were lower than those reported for clinical trials involving 
similar medications. Nevertheless, the types of AEs are 
similar, and there is no evidence to suggest that VA increased 
the frequency or severity of the known toxicities of the 
applied mAb or chemotherapeutic agents.
The types of AEs observed in the VA therapy group (eg, 
pruritus, skin reaction, and urticaria) are consistent with 
adverse drug reactions to intravenously administered VA 
preparations, as previously reported.30 The relative fre-
quency for patients experiencing an AE in the VA therapy 
group (42% of patients) is much higher than what we have 
published previously for intravenous VA (5%). This differ-
ence is because our previous study focused on VA-related 
AEs only, whereas the current study includes AEs caused 
by VA and by concomitant chemotherapy (42% of patients 
in the VA therapy group had concomitant chemotherapy 
plus supportive therapy and 17% of patients had concomi-
tant chemotherapy only).
Although we did not find any comparable studies in the 
literature, a number of groups have investigated whether 
VA preparations interact with traditional chemotherapy 
agents. Mansky et al16,31 have shown that combined therapy 
involving subcutaneous injections of VA (Helixor Abietis) 
and intravenously administered gemcitabine is well toler-
ated, and clinical response was similar to that for gem-
citabine alone. Importantly, the addition of VA did not affect 
the pharmacokinetics of gemcitabine at any of the VA dose 
levels tested (1-250 mg) and no botanical-drug interactions 
were observed. Our results differed from those reported by 
Mansky et al in that we did not observe a high incidence of 
local reactions or febrile and flu-like reactions, which are 
characteristic of subcutaneous administration of VA.32 As 
expected, because of the known toxicity profiles of cetux-
imab and panitumumab, we observed a higher incidence of 
skin disorders such as acneiform rash. The hematological 
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toxicity profile (leucopenia, anemia, and thrombocytope-
nia) was similar across all treatment groups (except for VA 
therapy) in both studies and is most likely a result of con-
comitant chemotherapy. A recent in vitro study investigated 
the effect of VA preparations on several commonly used 
chemotherapeutic agents in different cancer cell lines.33 It 
was found that VA preparations (Iscador Ltd) did not inhibit 
chemotherapy-induced cytostasis or cytotoxicity and 
showed an additive inhibitory effect at higher concentra-
tions of VA.
Because of the complex and nonstandardized nature of 
botanical drugs, prediction and identification of botanical-
drug interactions can be difficult. Adverse botanical-drug 
interactions often involve botanical-mediated induction or 
inhibition of hepatic and intestinal drug-metabolizing 
enzymes, such as cytochrome P450s (CYPs).34 However, 
previous in vitro investigations have shown that VA prepa-
rations have either no or minor effects on a range of CYPs, 
suggesting that VA-drug interactions based on drug metabo-
lism are unlikely.35,36 Furthermore, mAb do not undergo 
hepatic metabolism but undergo proteolytic catabolism 
throughout the body.37,38 As a result, it is generally believed 
that they are not subject to significant pharmacokinetic-type 
drug interactions.39
Although pharmacokinetic interactions may be less of a 
concern regarding combined VA and mAb, potential phar-
macodynamic interactions are important to consider. For 
example, vascular endothelial growth factor mAb, such as 
bevacizumab, are associated with causing hypertension, 
bleeding episodes, and thrombotic events and, therefore, 
should not be used with anticoagulants or following sur-
gery.40,41 A potential drug interaction of VA might be an 
additive hypotensive effect when combined with antihyper-
tensive drugs.42 Also, because application of VA can induce 
an innate immune response mediated by monocyte activa-
tion with a specific T-cell response,43,44 it has been sug-
gested that interactions be considered in coadministration 
with immunosuppressive drugs. Theoretically, none of 
these properties should negatively interact with the mAb 
included in our study; and in fact, a more active immune 
system, along with potential additive antitumor properties, 
might be beneficial to established anticancer protocols 
involving mAb and chemotherapy agents. VA preparations 
have been shown to inhibit the transmembrane efflux pump 
P-glycoprotein in vitro, an effect that in tissues exposed to 
chemotherapy agents, might result in an increased cytoplas-
mic drug concentration and cytotoxicity.45,46 Furthermore, a 
range of clinical studies reported a reduction in adverse 
drug reactions to conventional anticancer therapy and 
improved HRQL when VA therapy was given concomi-
tantly.12,13 The mechanisms involved in these possible ben-
efits of VA are not well understood but may include 
upregulation of endorphins, stimulation of the immune sys-
tem, stabilization of DNA, or psychological factors.12 
Although we observed a lower incidence of AEs in the VA 
plus mAb group compared with mAb alone, whether this 
was a result of VA is not clear from this study.
Conclusions
Results from our observational study found a reduced inci-
dence of AEs following exposure to mAb with VA com-
pared to mAb without VA and no unexpected AEs. These 
results are in line with the prediction, based on theoretical 
considerations, of no significant interactions occurring 
between VA and mAb. Future research should focus on 
investigating combined use of VA with specific mAb, in 
larger and more homogeneous patient groups in order to 
further elucidate the safety and effectiveness of this 
approach. Overall, the current results suggest that combined 
therapy with VA and mAb is safe.
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